- Home
- IRON vs APLS Comparison
IRON vs APLS Comparison
Compare IRON & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- APLS
- Stock Information
- Founded
- IRON 2017
- APLS 2009
- Country
- IRON United States
- APLS United States
- Employees
- IRON N/A
- APLS N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- APLS Health Care
- Exchange
- IRON Nasdaq
- APLS Nasdaq
- Market Cap
- IRON 2.1B
- APLS 2.2B
- IPO Year
- IRON N/A
- APLS 2017
- Fundamental
- Price
- IRON $59.76
- APLS $22.34
- Analyst Decision
- IRON Strong Buy
- APLS Buy
- Analyst Count
- IRON 12
- APLS 18
- Target Price
- IRON $92.08
- APLS $35.41
- AVG Volume (30 Days)
- IRON 330.3K
- APLS 2.5M
- Earning Date
- IRON 08-11-2025
- APLS 07-31-2025
- Dividend Yield
- IRON N/A
- APLS N/A
- EPS Growth
- IRON N/A
- APLS N/A
- EPS
- IRON N/A
- APLS N/A
- Revenue
- IRON N/A
- APLS $754,649,000.00
- Revenue This Year
- IRON N/A
- APLS $10.84
- Revenue Next Year
- IRON N/A
- APLS $10.51
- P/E Ratio
- IRON N/A
- APLS N/A
- Revenue Growth
- IRON N/A
- APLS 20.02
- 52 Week Low
- IRON $30.82
- APLS $16.10
- 52 Week High
- IRON $68.73
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- IRON 61.73
- APLS 69.42
- Support Level
- IRON $58.63
- APLS $18.48
- Resistance Level
- IRON $61.59
- APLS $20.40
- Average True Range (ATR)
- IRON 2.15
- APLS 1.17
- MACD
- IRON -0.14
- APLS 0.11
- Stochastic Oscillator
- IRON 64.07
- APLS 75.98
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.